Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E PTEN loss |
Therapy | GSK2636771 + unspecified PD-1 antibody |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E PTEN loss | melanoma | sensitive | GSK2636771 + unspecified PD-1 antibody | Preclinical | Actionable | In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196). | 26645196 |
PubMed Id | Reference Title | Details |
---|---|---|
(26645196) | Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. | Full reference... |